Patients with acute myocardial infarction (AMI) are at high risk for reinfarction and death, with the highest rate of death and reinfarction occurring within 30 days of AMI. Therapies that have been shown to reduce these risks (secondary prevention) continue to be underutilized. Nurse practitioners are well positioned to provide secondary prevention during and following hospitalization. The purpose of this pilot study was to examine the feasibility, acceptability, and preliminary effects of an NP delivered secondary prevention intervention. The specific objectives were: 1) to describe NP activities when delivering the secondary prevention intervention; 2) to evaluate the effect of the NP intervention on the rate of implementation of evidence-based secondary prevention treatment strategies and the patients’ achievement of secondary prevention target goals; and, 3) to examine the relationship between the NP activities delivering the intervention and secondary prevention goal achievement by patients. A prospective cohort design was used, in which patients’ achievement of target goals were compared between patients who received secondary prevention care from an NP and those who received usual care. The sample of convenience consisted of 65 patients with AMI. Data on practice activities and implementation of secondary prevention by the NP were collected before discharge from hospital and one week, two weeks, six weeks and 3 months after discharge. Data on patients’ achievement of goals were obtained before discharge from hospital and 3 months after discharge from both groups. This study’s results provide preliminary evidence that an NP delivered secondary prevention intervention, beginning prior to discharge and continuing for three months post myocardial infarction, significantly improves the implementation and uptake of guideline based secondary prevention treatments and risk factor reduction strategies. NP-led interventions such as this warrant replication. The unique contribution of the NP with this patient population is the training and skills needed to deliver all aspects of secondary prevention, including pharmacological and nonpharmacological therapies, without the immediate availability of a physician.

Patients with acute myocardial infarction (AMI) are at high risk for reinfarction and death, with the highest rate of death and reinfarction occurring within 30 days of AMI. Therapies that have been shown to reduce these risks (secondary prevention) continue to be underutilized. Nurse practitioners are well positioned to provide secondary prevention during and following hospitalization. The purpose of this pilot study was to examine the feasibility, acceptability, and preliminary effects of an NP delivered secondary prevention intervention. The specific objectives were: 1) to describe NP activities when delivering the secondary prevention intervention; 2) to evaluate the effect of the NP intervention on the rate of implementation of evidence-based secondary prevention treatment strategies and the patients’ achievement of secondary prevention target goals; and, 3) to examine the relationship between the NP activities delivering the intervention and secondary prevention goal achievement by patients. A prospective cohort design was used, in which patients’ achievement of target goals were compared between patients who received secondary prevention care from an NP and those who received usual care. The sample of convenience consisted of 65 patients with AMI. Data on practice activities and implementation of secondary prevention by the NP were collected before discharge from hospital and one week, two weeks, six weeks and 3 months after discharge. Data on patients’ achievement of goals were obtained before discharge from hospital and 3 months after discharge from both groups. This study’s results provide preliminary evidence that an NP delivered secondary prevention intervention, beginning prior to discharge and continuing for three months post myocardial infarction, significantly improves the implementation and uptake of guideline based secondary prevention treatments and risk factor reduction strategies. NP-led interventions such as this warrant replication. The unique contribution of the NP with this patient population is the training and skills needed to deliver all aspects of secondary prevention, including pharmacological and nonpharmacological therapies, without the immediate availability of a physician.

El Programa de Prevención y Rehabilitación Cardiaca Integral: CARDIOMOVE ; es una empresa de salud con fines de lucro que busca rentabilidad económica y social, cuyo objetivo es mejorar clínicamente al paciente; tanto del punto de vista cardiológico, como psicológico a quienes han sufrido de una cardiopatía isquémica como ; infarto o ataque al corazón, sometidos a una intervención coronaria percutáneo , cirugía de revascularización, angina crónica estable, implantación de dispositivo, trasplante cardiaco, insuficiencia cardíaca, intervención sobre válvulas cardiacas, enfermedad arterial periférica, y pacientes sin ninguna cardiopatía pero con factor de riesgo cardiovascular (hipertensión, diabetes mellitus , obesidad y dislipidemias) El Programa de Prevención y Rehabilitación cardíaca Integral: CARDIOMOVE; está compuesto por pilares fundamentales como el control de los factores de riesgo, la mejoría de la capacidad física, optimización del tratamiento médico, la educación de hábitos de vida saludable, y el soporte psicológico y nutricional. Nuestro servicio va dirigido para el público mayor de 18 años con cardiopatía o sin ella, pero con factor cardiovascular pertenecientes al nivel socioeconómico B y C de Lima Metropolitana con posibilidad de pago de bolsillo. El Programa de Prevención y Rehabilitación Cardíaca Integral: CARDIOMOVE: tiene su sede central localizada en el distrito de Jesús María, debido a que es un lugar de fácil acceso geográfico desde los distintos distritos de Lima. La idea de negocio, nace ante la prevalencia de enfermedades cardiovasculares, el aumento de factores de riesgo y pobre fomentación de estilos de vida saludable, ausencia de programas de rehabilitación prevención cardiovascular, ausencia de programa de rehabilitación cardiaca como estrategia de prevención secundaria demostrada, la desinformación sobre los grandes beneficios de la rehabilitación cardiaca ; la escasa derivación de pacientes a dichos programas casi inexistentes y el crecimiento de las enfermedades no transmisibles. Nuestra propuesta de valor es mejorar la calidad de vida; reincorporándolo laboral y socialmente; evitando el deterioro psicológico, fortaleciendo la capacidad física; brindando una experiencia única y segura; mediante una atención multidisciplinaria y personalizada a las personas que requieran un programa de prevención y rehabilitación cardiaca Integral. Todo esto es posible con un equipo humano profesional de salud y administrativo, cuyos valores principales son: Hospitalidad, Respeto, Responsabilidad, Calidad y Espiritualidad. Respecto a la evaluación económica financiera; se ha estimado una inversión de S/427,369 nuevos soles, el cual se financia 30% por capital y 70% por deuda. Con un precio promedio de venta por paquete completo del programa de prevención y rehabilitación cardíaca integral de S/. 1440 nuevos soles, un costo mensual de S/ 480 nuevos soles y un costo variable unitario promedio de S/. 40 nuevos soles. Con un tiempo de retorno de la inversión del segundo semestre del 1 año. Obteniendo un valor actual neto económico de la empresa de aproximadamente S/1,067.984nuevos soles. Respecto a la Tasa Interna de Retorno de la empresa corresponde de 30.83 %. Después de lo expuesto según los datos de rentabilidad financiera y estudios de sensibilidad, se concluye que se trata de una inversión de moderado riesgo con una gran posibilidad de crecimiento en el tiempo aunado a un gran impacto de salud de las personas. / The Comprehensive Cardiac Prevention and Rehabilitation Program: CARDIOMOVE; is a for-profit health company that seeks economic and social profitability, whose objective is to improve the patient clinically; both from a cardiological and psychological point of view to those who have suffered from ischemic heart disease such as; infarction or heart attack, undergoing percutaneous coronary intervention, bypass surgery, chronic stable angina, device implantation, heart transplantation, heart failure, intervention on heart valves, peripheral arterial disease, and patients without any heart disease but with a risk factor cardiovascular (hypertension, diabetes mellitus, obesity and dyslipidemias) The Comprehensive Cardiac Prevention and Rehabilitation Program: CARDIOMOVE; It is made up of fundamental pillars such as control of risk factors, improvement of physical capacity, optimization of medical treatment, education of healthy lifestyle habits, and psychological and nutritional support. Our service is aimed at the public over 18 years of age with or without heart disease, but with cardiovascular factors belonging to socioeconomic status B and C of Metropolitan Lima with the possibility of paying out of pocket. The Comprehensive Cardiac Prevention and Rehabilitation Program: CARDIOMOVE: has its headquarters located in the Jesús María district, due to the fact that it is a place with easy geographic access from the different districts of Lima. The business idea was born due to the prevalence of cardiovascular diseases, the increase in risk factors and poor promotion of healthy lifestyles, absence of cardiovascular prevention rehabilitation programs, absence of a cardiac rehabilitation program as a proven secondary prevention strategy, misinformation about the great benefits of cardiac rehabilitation; the scarce referral of patients to these programs almost non-existent and the growth of non-communicable diseases Our value proposition is to improve the quality of life; reincorporating him to work and socially; avoiding psychological deterioration, strengthening physical capacity; providing a unique and safe experience; through multidisciplinary and personalized care for people who require a comprehensive cardiac prevention and rehabilitation program. All this is possible with a professional health and administrative human team, whose main values ​​are: Hospitality, Respect, Responsibility, Quality and Spirituality. Regarding the financial economic evaluation; An investment of S / 427,369 nuevos soles has been estimated, which is financed 30% by capital and 70% by debt. With an average sale price for a complete package of the comprehensive cardiac prevention and rehabilitation program of S /. 1,440 nuevos soles, a monthly cost of S / 480 nuevos soles and an average unit variable cost of S /. 40 new soles. With a return on investment of 1 years. Obtaining a net present economic value of the company of approximately S / 1,067.984 new soles. Regarding the Internal Rate of Return of the company it corresponds to 30.83%. After the above, according to the financial profitability data and sensitivity studies, it is concluded that it is a low risk investment with a great possibility of growth over time coupled with a great impact on people's health. / Trabajo de investigación

Vinte e seis pacientes com cardiomiopatia hipertrófica e fatores de risco de morte súbita, foram submetidos a implante de cardioversor-desfibrilador implantável de dupla-câmara, com seguimento médio de 19 meses. Observou-se quatro choques em arritmias letais, 4 pacientes apresentaram TVNS e 5 taquiarritmias supraventriculares. Ocorreu um óbito.Conclusões: Observamos: TPSV em 19,2%; TVNS em 15,4% e TVS/FV em 15,4%. Nenhuma variável clínica ou demográfica, discriminou o comportamento clínico ou funcional pós-implante de CDI; a recorrência de síncope pós implante de CDI, não se associou à presença de eventos arrítmicos e a hipertrofia maior que 30 mm se associou à choque precoce do CDI (p=0,003). / During 19 months of average follow-up period, we followed 26 patients with hypertrophic cardiomyopathy and high risk for sudden death, all treated by dual chamber implantable cardioverter-defibrillator. 4 patients had received appropriate ICD discharge, 4 patients with NSVT and 5 supraventricular arrhythmias. One death had occurred. Conclusions: we observed: supraventricular arrhythmias in 19,2%; NSVT in 15,4% and VT/VF in 15,4%. The clinical or demographic outcomes did not suggest any clinical or functional results after ICD implantation; syncope may occur after ICD implantation and no arrhythmias recordered by intracardiac electrograms and left-ventricular-wall thickness greater than 30 mm is associated with early ICD shocks (p=0,003).

Vinte e seis pacientes com cardiomiopatia hipertrófica e fatores de risco de morte súbita, foram submetidos a implante de cardioversor-desfibrilador implantável de dupla-câmara, com seguimento médio de 19 meses. Observou-se quatro choques em arritmias letais, 4 pacientes apresentaram TVNS e 5 taquiarritmias supraventriculares. Ocorreu um óbito.Conclusões: Observamos: TPSV em 19,2%; TVNS em 15,4% e TVS/FV em 15,4%. Nenhuma variável clínica ou demográfica, discriminou o comportamento clínico ou funcional pós-implante de CDI; a recorrência de síncope pós implante de CDI, não se associou à presença de eventos arrítmicos e a hipertrofia maior que 30 mm se associou à choque precoce do CDI (p=0,003). / During 19 months of average follow-up period, we followed 26 patients with hypertrophic cardiomyopathy and high risk for sudden death, all treated by dual chamber implantable cardioverter-defibrillator. 4 patients had received appropriate ICD discharge, 4 patients with NSVT and 5 supraventricular arrhythmias. One death had occurred. Conclusions: we observed: supraventricular arrhythmias in 19,2%; NSVT in 15,4% and VT/VF in 15,4%. The clinical or demographic outcomes did not suggest any clinical or functional results after ICD implantation; syncope may occur after ICD implantation and no arrhythmias recordered by intracardiac electrograms and left-ventricular-wall thickness greater than 30 mm is associated with early ICD shocks (p=0,003).